Next Article in Journal
IMSI—Guidelines for Sperm Quality Assessment
Next Article in Special Issue
Editorial of Special Issue “Multiple Sclerosis: From Diagnostic Biomarkers to Imaging and Clinical Predictors”
Previous Article in Journal
Multiplex Lateral Flow Immunoassay for the Detection of Expanded-Spectrum Hydrolysis and CTX-M Enzymes
Previous Article in Special Issue
Information Processing Speed Assessed with Letter Digit Substitution Test in Croatian Sample of Multiple Sclerosis Patients
 
 
Article
Peer-Review Record

Clinical Predictors of Neurogenic Lower Urinary Tract Dysfunction in Persons with Multiple Sclerosis

Diagnostics 2022, 12(1), 191; https://doi.org/10.3390/diagnostics12010191
by Janina Beck 1,†, Anke Kirsten Jaekel 1,2,*,†, Federico Leopoldo Zeller 2, Michael Kowollik 2, Ines Kurze 3, Albert Kaufmann 4, Wolfgang Feneberg 5, Anna Brandt 6, Peter Flachenecker 7, Thomas Henze 8, Burkhard Domurath 9, Paul Schmidt 10, Will Nelson Vance 9, Franziska Goldschmidt 1, Ruth Klara Maria Kirschner-Hermanns 1,2 and Stephanie C. Knüpfer 1
Reviewer 1:
Reviewer 2: Anonymous
Diagnostics 2022, 12(1), 191; https://doi.org/10.3390/diagnostics12010191
Submission received: 30 November 2021 / Revised: 5 January 2022 / Accepted: 11 January 2022 / Published: 13 January 2022
(This article belongs to the Special Issue Multiple Sclerosis Diagnostics)

Round 1

Reviewer 1 Report

This manuscript shows the clinical parameters predicting progression of lower urinary tract dysfunction in patients with multiple sclerosis. The purpose of this study may be useful and contribute to treatment of lower urinary tract dysfunction with MS. However, there are several concerns related to the study design and discussion.

  1. Please summarize the baseline characteristics of all 207 MS patients in new Table (age, sex, BMI, diseases, etc).
  2. In addition, please summarize all raw data of bladder diary, uroflowmetry, EDSS etc in details.
  3. Table 1 is not necessary. Please replace it to patient characteristics (new Table 1).
  4. Table 2 is not necessary. Please replace it to raw data of objective parameters (new Table 2).
  5. Please show why the authors chose cut-off of EDSS as 5.
  6. Also, why 250, 500 ml of voided volume? New table of data including bladder diary, uroflowmetry, EDSS could help to lead to cut-off level.
  7. Other your cut-off values are same. Please define these.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors aimed to identify clinical parameters indicative of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.

As they stated neither global threshold value of EDSS exists, nor the clinical value with regard to storage and voiding symptoms is still unclear.

They found that bladder diary and urinary tract infection rate should be routinely assessed to identify patients who require urodynamics.

From this point of view, this report is interesting.

This paper has the potential to be widely applied in the future.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The authors have revised accordingly.

Back to TopTop